SIU Opens Enrollment in National Psoriasis Study

Print

June 11, 2013                                                         

 

SIU Opens Enrollment in National Psoriasis Study

Individuals who are diagnosed with moderate to severe psoriasis are needed to participate in a national, multi-site study of the investigational drug Apremilast at Southern Illinois University School of Medicine.  The investigational drug is being evaluated for its effectiveness in the treatment of psoriasis by the SIU Division of Dermatology. Psoriasis is a common, chronic skin disorder which is caused by an overactive immune system. Psoriasis is commonly seen as red and white scaly patches on the skin.

“This study will give us a better understanding about psoriasis and hopefully lead to better treatment options,” said Dr. Stephen Stone, professor of dermatology at SIU, who is directing the study.

Volunteers must be age 18 and older. They must have had psoriasis for at least 12 months and have had no prior exposure to biologics for treatment of psoriatic arthritis or psoriasis.

Each participant will receive a physical examination and other tests prior to starting in the pharmaceutical study and during follow-up visits once a week for 16 weeks and then at various additional times for two years. There will be no charge to participants for the tests and medications related to the study, which is sponsored by Celgene Corporation.

Anyone interested in participating in the study, should contact Lori Miedwig at lmiedwig@siumed.edu or call 217-545-4402 weekdays.

Phone 217-545-8000
P.O. Box 19620
Springfield, IL 62794-9620
The mission of SIU School of Medicine is to assist the citizens of central and southern Illinois in meeting their health-care needs through education, patient care, research and service to the community.

Connect

Connect on FacebookMore About SIU SOM on YouTubeSIU Blogtwitter